Patients are being recruited for Phase 2 of Toca 5, a trial investigating the effectiveness of immunotherapy in the treatment of brain cancer
A Phase 2/3 clinical trial called Toca 5 – investigating a retroviral gene therapy treatment in patients with recurrent brain cancer – is actively enrolling at Atlantic NeuroSurgical Specialists (ANS).
According to Dr. Yaron Moshel, a neurosurgeon at ANS and co-director of the Brain Tumor Center of New Jersey, the second phase of this trial sponsored by Tocagen Inc. follows on the heels of a successful first phase. The study compares immunotherapy that uses a retrovirus designed to selectively infect and kill proliferating cancer cells and stimulate a patient’s own immune system to attack recurring high-grade gliomas – glioblastoma and anaplastic astrocytoma – to the current standard of care.
“Chemotherapy and other traditional therapies have had only limited success in treating these most common and aggressive forms of brain cancer,” Dr. Moshel explains. “Phase 1 of the Toca 5 trial showed complete and partial tumor shrinkage and extended survival in patients as compared to other standard therapies.”
In 2016, approximately 160,000 patients are expected to be diagnosed with high-grade gliomas worldwide. With the current standard of care, newly diagnosed patients with glioblastomas have a median survival of approximately 14 to 16 months. After recurrence, median survival is typically seven to nine months.
“The Phase 1 results of this promising immunotherapy reported a 40 percent probability of survival at two years for patients with recurrent glioblastoma,” Dr. Moshel continues. “It’s been very hard to get these kinds of results with such an aggressive and challenging type of tumor, so we are really excited by what we are seeing.”
These clinical trial participants followed a therapeutic regimen that involves two discrete steps combining injection of Toca 511 into the tumor cavity during surgery and orally administered courses of Toca FC after surgery. Toca 511 is a retrovirus that selectively infects proliferating cancer cells and reprograms tumor cells with a chemotherapy-activating gene. Toca FC, which is given after surgery, is an extended-release precursor-drug that only gets converted to the active chemotherapy drug within infected tumor cells that have the encoded gene. Within the tumor micro-environment, the regimen selectively kills cancer cells and activates the immune system against cancer while leaving healthy cells unharmed.
ANS is now recruiting patients with recurrent glioblastomas or anaplastic astrocytoma for Phase 2 of the trial. A patient may qualify for this study if he/she:
- Has glioblastoma or anaplastic astrocytoma at first or second recurrence (including this recurrence)
- Has had prior surgery, radiation, and chemotherapy
- Is between 18 years old and 75 years old
“Immunotherapy and retroviral delivery of gene therapy holds great promise in opening the door to new treatment options for patients suffering from this devastating disease,” Dr. Moshel concludes. “Our dedicated brain tumor team at ANS – and our colleagues worldwide – are encouraged by this innovative approach and the promise it holds for what has been a challenging battle with limited options for treating these kinds of tumors.”
For more information, contact the ANS Brain Tumor Center at 973-285-7816 and visit http://www.ansdocs.com/tocagen.php and www.tocagen.com/toca5.
Atlantic NeuroSurgical Specialists (ANS) is New Jersey’s largest neurosurgical practice and one of the most advanced in the country. Since its founding in 1958, ANS has specialized in the diagnosis and treatment of disorders affecting the nervous system. Its Brain Tumor Center – co-directed by Yaron A. Moshel, MD, PhD and Brian D. Beyerl, MD, FACS – is known for its cutting edge treatments and therapies, many of which involve minimally invasive. ANS sponsors The Center for Hope Foundation, a dedicated support group for brain tumor patients and their families.